

# Yuzhuo Wang

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/7061026/yuzhuo-wang-publications-by-citations.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

201  
papers

11,318  
citations

59  
h-index

100  
g-index

226  
ext. papers

13,497  
ext. citations

7.6  
avg, IF

5.92  
L-index

#	Paper	IF	Citations
201	Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. <i>Cancer Discovery</i> , <b>2011</b> , 1, 487-95	24.4	550
200	Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. <i>Nature</i> , <b>2015</b> , 518, 422-6	50.4	451
199	Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. <i>Cancer Cell</i> , <b>2010</b> , 17, 535-46	24.3	377
198	Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 2315-24	12.9	334
197	The x(c)- cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases. <i>Journal of Cellular Physiology</i> , <b>2008</b> , 215, 593-602	7	293
196	High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. <i>Cancer Research</i> , <b>2014</b> , 74, 1272-83	10.1	250
195	Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , <b>2004</b> , 92, 221-36	5.1	242
194	Cell differentiation lineage in the prostate. <i>Differentiation</i> , <b>2001</b> , 68, 270-9	3.5	222
193	Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. <i>JAMA Oncology</i> , <b>2015</b> , 1, 466-74	13.4	207
192	Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer. <i>Oncotarget</i> , <b>2014</b> , 5, 764-74	3.3	184
191	Cancer-generated lactic acid: a regulatory, immunosuppressive metabolite?. <i>Journal of Pathology</i> , <b>2013</b> , 230, 350-5	9.4	178
190	Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling. <i>FASEB Journal</i> , <b>2008</b> , 22, 1512-20	0.9	174
189	The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer. <i>Cancer Discovery</i> , <b>2017</b> , 7, 54-71	24.4	173
188	Translational Activation of HIF1 $\alpha$ by YB-1 Promotes Sarcoma Metastasis. <i>Cancer Cell</i> , <b>2015</b> , 27, 682-97	24.3	167
187	MicroRNAs associated with metastatic prostate cancer. <i>PLoS ONE</i> , <b>2011</b> , 6, e24950	3.7	163
186	Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. <i>Cancer Research</i> , <b>2009</b> , 69, 8386-94	10.1	161
185	The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer. <i>Cell Reports</i> , <b>2015</b> , 12, 922-36	10.6	155

184	YB-1 regulates stress granule formation and tumor progression by translationally activating G3BP1. <i>Journal of Cell Biology</i> , <b>2015</b> , 208, 913-29	7.3	154
183	Estrogen receptor-beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFalpha mediated. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 3123-8	11.5	153
182	Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 1442-51	12.9	150
181	The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. <i>Cancer Research</i> , <b>2007</b> , 67, 967-75	10.1	150
180	Paracrine regulation of apoptosis by steroid hormones in the male and female reproductive system. <i>Cell Death and Differentiation</i> , <b>2001</b> , 8, 192-200	12.7	150
179	Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation. <i>Nature Medicine</i> , <b>2017</b> , 23, 1055-1062	50.5	149
178	Development and characterization of efficient xenograft models for benign and malignant human prostate tissue. <i>Prostate</i> , <b>2005</b> , 64, 149-59	4.2	147
177	Evidence that epithelial and mesenchymal estrogen receptor-alpha mediates effects of estrogen on prostatic epithelium. <i>Developmental Biology</i> , <b>2001</b> , 229, 432-42	3.1	144
176	From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. <i>Journal of Pathology</i> , <b>2012</b> , 227, 286-97	9.4	142
175	The xc- cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance. <i>British Journal of Cancer</i> , <b>2008</b> , 99, 464-72	8.7	132
174	Lessons from patient-derived xenografts for better in vitro modeling of human cancer. <i>Advanced Drug Delivery Reviews</i> , <b>2014</b> , 79-80, 222-37	18.5	126
173	Engineering Multifunctional RNAi Nanomedicine To Concurrently Target Cancer Hallmarks for Combinatorial Therapy. <i>Angewandte Chemie - International Edition</i> , <b>2018</b> , 57, 1510-1513	16.4	117
172	SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition. <i>European Urology</i> , <b>2017</b> , 71, 68-78	10.2	105
171	Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails. <i>Oncogene</i> , <b>2010</b> , 29, 3593-604	9.2	103
170	Plasma miRNAs as biomarkers to identify patients with castration-resistant metastatic prostate cancer. <i>International Journal of Molecular Sciences</i> , <b>2013</b> , 14, 7757-70	6.3	98
169	An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. <i>Laboratory Investigation</i> , <b>2005</b> , 85, 1392-404	5.9	95
168	Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 4043-54	12.9	94
167	REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer. <i>Nucleic Acids Research</i> , <b>2014</b> , 42, 999-1015	20.1	93

166	Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 1675-87 <sup>12.9</sup>	90
165	Sex hormone-induced prostatic carcinogenesis in the noble rat: the role of insulin-like growth factor-I (IGF-I) and vascular endothelial growth factor (VEGF) in the development of prostate cancer. <i>Prostate</i> , <b>1998</b> , 35, 165-77	4.2 90
164	The xc- cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2009</b> , 64, 463-72	3.5 86
163	Sulfasalazine-induced cystine starvation: potential use for prostate cancer therapy. <i>Prostate</i> , <b>2007</b> , 67, 162-71	4.2 85
162	hZimp10 is an androgen receptor co-activator and forms a complex with SUMO-1 at replication foci. <i>EMBO Journal</i> , <b>2003</b> , 22, 6101-14	13 85
161	Comprehensive analysis of mammalian miRNA* species and their role in myeloid cells. <i>Blood</i> , <b>2011</b> , 118, 3350-8	2.2 81
160	Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. <i>Gynecologic Oncology</i> , <b>2005</b> , 96, 48-55	4.9 80
159	The role of epigenetics and long noncoding RNA MIAT in neuroendocrine prostate cancer. <i>Epigenomics</i> , <b>2016</b> , 8, 721-31	4.4 80
158	Steroid hormones stimulate human prostate cancer progression and metastasis. <i>International Journal of Cancer</i> , <b>2006</b> , 118, 2123-31	7.5 79
157	The non-coding transcriptome as a dynamic regulator of cancer metastasis. <i>Cancer and Metastasis Reviews</i> , <b>2014</b> , 33, 1-16	9.6 74
156	miR-188-5p inhibits tumour growth and metastasis in prostate cancer by repressing LAPTM4B expression. <i>Oncotarget</i> , <b>2015</b> , 6, 6092-104	3.3 73
155	ASAP1, a gene at 8q24, is associated with prostate cancer metastasis. <i>Cancer Research</i> , <b>2008</b> , 68, 4352-9 <sup>10.1</sup>	73
154	ONECUT2 is a driver of neuroendocrine prostate cancer. <i>Nature Communications</i> , <b>2019</b> , 10, 278	17.4 72
153	Polycomb-mediated silencing in neuroendocrine prostate cancer. <i>Clinical Epigenetics</i> , <b>2015</b> , 7, 40	7.7 70
152	Growth factors and epithelial-stromal interactions in prostate cancer development. <i>International Review of Cytology</i> , <b>2000</b> , 199, 65-116	70
151	Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 783-91	12.9 64
150	Estrogenic effects on prostatic differentiation and carcinogenesis. <i>Reproduction, Fertility and Development</i> , <b>2001</b> , 13, 285-96	1.8 64
149	Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. <i>PLoS ONE</i> , <b>2011</b> , 6, e21121	3.7 63

148	Expression and function of the progesterone receptor in human prostate stroma provide novel insights to cell proliferation control. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2013</b> , 98, 2887-96	5.6	62
147	The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors. <i>International Journal of Cancer</i> , <b>2015</b> , 136, E27-38	7.5	61
146	Elevated expression of the centromere protein-A(CENP-A)-encoding gene as a prognostic and predictive biomarker in human cancers. <i>International Journal of Cancer</i> , <b>2016</b> , 139, 899-907	7.5	60
145	The long non-coding RNA PCGEM1 is regulated by androgen receptor activity in vivo. <i>Molecular Cancer</i> , <b>2015</b> , 14, 46	42.1	59
144	ERBB4 confers metastatic capacity in Ewing sarcoma. <i>EMBO Molecular Medicine</i> , <b>2013</b> , 5, 1087-102	12	59
143	Androgen hormone action in prostatic carcinogenesis: stromal androgen receptors mediate prostate cancer progression, malignant transformation and metastasis. <i>Carcinogenesis</i> , <b>2012</b> , 33, 1391-8	4.6	59
142	The MCT4 Gene: A Novel, Potential Target for Therapy of Advanced Prostate Cancer. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 2721-33	12.9	57
141	Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer. <i>Genome Biology</i> , <b>2014</b> , 15, 426	18.3	57
140	The evolution of long noncoding RNA acceptance in prostate cancer initiation, progression, and its clinical utility in disease management. <i>European Urology</i> , <b>2019</b> , 76, 546-559	10.2	56
139	Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. <i>Science Translational Medicine</i> , <b>2019</b> , 11,	17.5	56
138	Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy. <i>Gynecologic Oncology</i> , <b>2008</b> , 110, 256-64	4.9	54
137	Genistein increases epidermal growth factor receptor signaling and promotes tumor progression in advanced human prostate cancer. <i>PLoS ONE</i> , <b>2011</b> , 6, e20034	3.7	52
136	Steroid hormones and carcinogenesis of the prostate: the role of estrogens. <i>Differentiation</i> , <b>2007</b> , 75, 871-82	3.5	52
135	BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma. <i>Genome Medicine</i> , <b>2019</b> , 11, 8	14.4	52
134	Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease. <i>Blood</i> , <b>2016</b> , 127, 2203-13	2.2	51
133	The BMP family member Gdf7 is required for seminal vesicle growth, branching morphogenesis, and cytodifferentiation. <i>Developmental Biology</i> , <b>2001</b> , 234, 138-50	3.1	49
132	GATA2 as a potential metastasis-driving gene in prostate cancer. <i>Oncotarget</i> , <b>2014</b> , 5, 451-61	3.3	49
131	Integrin-linked kinase as a target for ERG-mediated invasive properties in prostate cancer models. <i>Carcinogenesis</i> , <b>2012</b> , 33, 2558-67	4.6	46

130	Decitabine-induced demethylation of 5' CpG island in GADD45A leads to apoptosis in osteosarcoma cells. <i>Neoplasia</i> , <b>2008</b> , 10, 471-80	6.4	45
129	Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer. <i>Clinical Epigenetics</i> , <b>2016</b> , 8, 16	7.7	44
128	Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models. <i>Prostate</i> , <b>2018</b> , 78, 1262-1282	4.2	44
127	Quantitation of apoptotic activity following castration in human prostatic tissue in vivo. <i>Prostate</i> , <b>2003</b> , 54, 212-9	4.2	44
126	Neuroendocrine differentiation of prostate cancer leads to PSMA suppression. <i>Endocrine-Related Cancer</i> , <b>2018</b> , 26, 131-146	5.7	44
125	Class I HDAC inhibitors enhance YB-1 acetylation and oxidative stress to block sarcoma metastasis. <i>EMBO Reports</i> , <b>2019</b> , 20, e48375	6.5	44
124	A novel protein isoform of the multicopy human NAIP gene derives from intragenic Alu SINE promoters. <i>PLoS ONE</i> , <b>2009</b> , 4, e5761	3.7	43
123	Long non-coding RNAs in the doxorubicin resistance of cancer cells. <i>Cancer Letters</i> , <b>2021</b> , 508, 104-114	9.9	42
122	The immunoregulatory mechanisms of carcinoma for its survival and development. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2011</b> , 30, 12	12.8	41
121	Multiplexed quantum dot labeling of activated c-Met signaling in castration-resistant human prostate cancer. <i>PLoS ONE</i> , <b>2011</b> , 6, e28670	3.7	41
120	Modulation by decitabine of gene expression and growth of osteosarcoma U2OS cells in vitro and in xenografts: identification of apoptotic genes as targets for demethylation. <i>Cancer Cell International</i> , <b>2007</b> , 7, 14	6.4	40
119	Lactic Acid and an Acidic Tumor Microenvironment suppress Anticancer Immunity. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	40
118	The epigenetic/noncoding origin of tumor dormancy. <i>Trends in Molecular Medicine</i> , <b>2015</b> , 21, 206-11	11.5	39
117	Poly-gene fusion transcripts and chromothripsis in prostate cancer. <i>Genes Chromosomes and Cancer</i> , <b>2012</b> , 51, 1144-53	5	39
116	The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer. <i>EMBO Molecular Medicine</i> , <b>2019</b> , 11, e10659	12	37
115	Prognostication of prostate cancer based on NUCB2 protein assessment: NUCB2 in prostate cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2013</b> , 32, 77	12.8	37
114	Developmental and androgenic regulation of chromatin regulators EZH2 and ANCCA/ATAD2 in the prostate Via MLL histone methylase complex. <i>Prostate</i> , <b>2013</b> , 73, 455-66	4.2	36
113	Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer. <i>European Urology</i> , <b>2018</b> , 73, 524-532	10.2	35

112	The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications. <i>GigaScience</i> , <b>2018</b> , 7,	7.6	35
111	Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2018</b> , 17, 2746-2755	6.1	34
110	Integrated analysis of the prostate cancer small-nucleolar transcriptome reveals SNORA55 as a driver of prostate cancer progression. <i>Molecular Oncology</i> , <b>2016</b> , 10, 693-703	7.9	33
109	The diverse heterogeneity of molecular alterations in prostate cancer identified through next-generation sequencing. <i>Asian Journal of Andrology</i> , <b>2013</b> , 15, 301-8	2.8	33
108	Bisphenol A induces permanent squamous change in mouse prostatic epithelium. <i>Differentiation</i> , <b>2007</b> , 75, 745-56	3.5	33
107	Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer. <i>Oncotarget</i> , <b>2015</b> , 6, 1806-20	3.3	33
106	Heterochromatin Protein 1 Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer. <i>Cancer Research</i> , <b>2018</b> , 78, 2691-2704	10.1	31
105	Crosstalk between nuclear MET and SOX9/Eatenin correlates with castration-resistant prostate cancer. <i>Molecular Endocrinology</i> , <b>2014</b> , 28, 1629-39		31
104	Targeting MCT4 to reduce lactic acid secretion and glycolysis for treatment of neuroendocrine prostate cancer. <i>Cancer Medicine</i> , <b>2018</b> , 7, 3385	4.8	30
103	Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance. <i>Journal of Thoracic Oncology</i> , <b>2013</b> , 8, 161-70	8.9	30
102	Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target. <i>Molecular Cancer Therapeutics</i> , <b>2012</b> , 11, 775-83	6.1	30
101	Development of metastatic and non-metastatic tumor lines from a patient's prostate cancer specimen-identification of a small subpopulation with metastatic potential in the primary tumor. <i>Prostate</i> , <b>2010</b> , 70, 1636-44	4.2	30
100	Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies. <i>Oncotarget</i> , <b>2015</b> , 6, 21522-32	3.3	30
99	Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 595-608	12.9	29
98	An actionable sterol-regulated feedback loop modulates statin sensitivity in prostate cancer. <i>Molecular Metabolism</i> , <b>2019</b> , 25, 119-130	8.8	28
97	INPP4B suppresses prostate cancer cell invasion. <i>Cell Communication and Signaling</i> , <b>2014</b> , 12, 61	7.5	28
96	CSF1 expression in nongynecological leiomyosarcoma is associated with increased tumor angiogenesis. <i>American Journal of Pathology</i> , <b>2011</b> , 179, 2100-7	5.8	28
95	Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers. <i>Current Cancer Drug Targets</i> , <b>2006</b> , 6, 455-89	2.8	28

94	Rescue of embryonic epithelium reveals that the homozygous deletion of the retinoblastoma gene confers growth factor independence and immortality but does not influence epithelial differentiation or tissue morphogenesis. <i>Journal of Biological Chemistry</i> , <b>2002</b> , 277, 44475-84	5.4	28
93	Increased PrLZ-mediated androgen receptor transactivation promotes prostate cancer growth at castration-resistant stage. <i>Carcinogenesis</i> , <b>2013</b> , 34, 257-67	4.6	27
92	Therapeutic Antibodies Targeting CSF1 Impede Macrophage Recruitment in a Xenograft Model of Tenosynovial Giant Cell Tumor. <i>Sarcoma</i> , <b>2010</b> , 2010, 174528	3.1	26
91	Collagen triple helix repeat containing 1 promotes melanoma cell adhesion and survival. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2011</b> , 15, 103-10	1.6	26
90	The ontogeny of the urogenital system of the spotted hyena ( <i>Crocuta crocuta</i> Erxleben). <i>Biology of Reproduction</i> , <b>2005</b> , 73, 554-64	3.9	26
89	Differential Expression of Glucose Transporters and Hexokinases in Prostate Cancer with a Neuroendocrine Gene Signature: A Mechanistic Perspective for F-FDG Imaging of PSMA-Suppressed Tumors. <i>Journal of Nuclear Medicine</i> , <b>2020</b> , 61, 904-910	8.9	26
88	miR-100-5p inhibition induces apoptosis in dormant prostate cancer cells and prevents the emergence of castration-resistant prostate cancer. <i>Scientific Reports</i> , <b>2017</b> , 7, 4079	4.9	25
87	Drug sensitivity testing for personalized lung cancer therapy. <i>Journal of Thoracic Disease</i> , <b>2012</b> , 4, 17-8	2.6	25
86	Inhibition of Transient Receptor Potential Vanilloid 6 channel, elevated in human ovarian cancers, reduces tumour growth in a xenograft model. <i>Journal of Cancer</i> , <b>2018</b> , 9, 3196-3207	4.5	25
85	The BIRC6 gene as a novel target for therapy of prostate cancer: dual targeting of inhibitors of apoptosis. <i>Oncotarget</i> , <b>2014</b> , 5, 6896-908	3.3	24
84	ETS transcription factors as emerging drug targets in cancer. <i>Medicinal Research Reviews</i> , <b>2020</b> , 40, 413-430	4.4	24
83	Urogenital system of the spotted hyena ( <i>Crocuta crocuta</i> Erxleben): a functional histological study. <i>Journal of Morphology</i> , <b>2003</b> , 256, 205-18	1.6	23
82	Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer. <i>European Urology</i> , <b>2020</b> , 78, 834-844	10.2	23
81	BIRC6 protein, an inhibitor of apoptosis: role in survival of human prostate cancer cells. <i>PLoS ONE</i> , <b>2013</b> , 8, e55837	3.7	22
80	Next generation patient-derived prostate cancer xenograft models. <i>Asian Journal of Andrology</i> , <b>2014</b> , 16, 407-12	2.8	22
79	The long noncoding RNA HORAS5 mediates castration-resistant prostate cancer survival by activating the androgen receptor transcriptional program. <i>Molecular Oncology</i> , <b>2019</b> , 13, 1121-1136	7.9	21
78	Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient-derived, advanced prostate cancer tissue xenograft model. <i>Molecular Oncology</i> , <b>2014</b> , 8, 311-22	7.9	21
77	Use of irinotecan for treatment of small cell carcinoma of the prostate. <i>Prostate</i> , <b>2011</b> , 71, 675-81	4.2	21



76	Subrenal capsule grafting technology in human cancer modeling and translational cancer research. <i>Differentiation</i> , <b>2016</b> , 91, 15-9	3.5	21
75	Engineering Multifunctional RNAi Nanomedicine To Concurrently Target Cancer Hallmarks for Combinatorial Therapy. <i>Angewandte Chemie</i> , <b>2018</b> , 130, 1526-1529	3.6	20
74	Induction of neuronal apoptosis inhibitory protein expression in response to androgen deprivation in prostate cancer. <i>Cancer Letters</i> , <b>2010</b> , 292, 176-85	9.9	20
73	Epithelial immune cell-like transition (EIT): a proposed transdifferentiation process underlying immune-suppressive activity of epithelial cancers. <i>Differentiation</i> , <b>2012</b> , 83, 293-8	3.5	19
72	Polycomb genes are associated with response to imatinib in chronic myeloid leukemia. <i>Epigenomics</i> , <b>2015</b> , 7, 757-65	4.4	18
71	The role of mRNA splicing in prostate cancer. <i>Asian Journal of Andrology</i> , <b>2014</b> , 16, 515-21	2.8	18
70	Switching off malignant mesothelioma: exploiting the hypoxic microenvironment. <i>Genes and Cancer</i> , <b>2016</b> , 7, 340-354	2.9	18
69	Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 1542-1551	12.9	17
68	Deletion of leucine zipper tumor suppressor 2 (Lzts2) increases susceptibility to tumor development. <i>Journal of Biological Chemistry</i> , <b>2013</b> , 288, 3727-38	5.4	17
67	SRRM4 gene expression correlates with neuroendocrine prostate cancer. <i>Prostate</i> , <b>2019</b> , 79, 96-104	4.2	16
66	A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agents. <i>Journal of Physical Education and Sports Management</i> , <b>2017</b> , 3,	2.8	15
65	Patient-derived xenografts: A platform for accelerating translational research in prostate cancer. <i>Molecular and Cellular Endocrinology</i> , <b>2018</b> , 462, 17-24	4.4	14
64	Oncogenes and tumor suppressor genes in prostate cancer: a review. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>1997</b> , 3, 41-6	2.8	14
63	Systematic identification and characterization of RNA editing in prostate tumors. <i>PLoS ONE</i> , <b>2014</b> , 9, e101431	3.7	14
62	Genistein versus ICI 182, 780: an ally or enemy in metastatic progression of prostate cancer. <i>Prostate</i> , <b>2013</b> , 73, 1747-60	4.2	13
61	Molecular analysis and characterization of PrEC, commercially available prostate epithelial cells. <i>In Vitro Cellular and Developmental Biology - Animal</i> , <b>2006</b> , 42, 33-9	2.6	13
60	Prognostic relevance of a T-type calcium channels gene signature in solid tumours: A correlation ready for clinical validation. <i>PLoS ONE</i> , <b>2017</b> , 12, e0182818	3.7	13
59	Androgen receptor transcriptionally regulates semaphorin 3C in a GATA2-dependent manner. <i>Oncotarget</i> , <b>2017</b> , 8, 9617-9633	3.3	13

58	RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression. <i>European Urology</i> , <b>2019</b> , 76, 157-166	10.2	12
57	Metabolic heterogeneity signature of primary treatment-naïve prostate cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 25928-25941	3.3	12
56	EZH2 inhibition: a promising strategy to prevent cancer immune editing. <i>Epigenomics</i> , <b>2020</b> , 12, 1457-1476	4.4	12
55	The long and short non-coding RNAs modulating EZH2 signaling in cancer.. <i>Journal of Hematology and Oncology</i> , <b>2022</b> , 15, 18	22.4	12
54	PKMYT1 is associated with prostate cancer malignancy and may serve as a therapeutic target. <i>Gene</i> , <b>2020</b> , 744, 144608	3.8	11
53	A noncanonical AR addiction drives enzalutamide resistance in prostate cancer. <i>Nature Communications</i> , <b>2021</b> , 12, 1521	17.4	11
52	Molecular events in neuroendocrine prostate cancer development. <i>Nature Reviews Urology</i> , <b>2021</b> , 18, 581-596	5.5	11
51	An Aqueous Extract of Marine Microalgae Exhibits Antimetastatic Activity through Preferential Killing of Suspended Cancer Cells and Anticolony Forming Activity. <i>Evidence-based Complementary and Alternative Medicine</i> , <b>2016</b> , 2016, 9730654	2.3	11
50	Transmembrane and coiled-coil domain family 1 is a novel protein of the endoplasmic reticulum. <i>PLoS ONE</i> , <b>2014</b> , 9, e85206	3.7	10
49	Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer.. <i>Nature</i> , <b>2021</b> ,	50.4	10
48	Immune phenotypes of prostate cancer cells: Evidence of epithelial immune cell-like transition?. <i>Asian Journal of Urology</i> , <b>2016</b> , 3, 195-202	2.7	10
47	The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.. <i>Nature Communications</i> , <b>2021</b> , 12, 7349	17.4	10
46	Exonuclease 1 expression is associated with clinical progression, metastasis, and survival prognosis of prostate cancer. <i>Journal of Cellular Biochemistry</i> , <b>2019</b> , 120, 11383	4.7	9
45	Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4. <i>Neoplasia</i> , <b>2020</b> , 22, 253-262	6.4	9
44	A synopsis of prostate organoid methodologies, applications, and limitations. <i>Prostate</i> , <b>2020</b> , 80, 518-526	4.2	9
43	Treatment with docetaxel in combination with Aneustat leads to potent inhibition of metastasis in a patient-derived xenograft model of advanced prostate cancer. <i>British Journal of Cancer</i> , <b>2018</b> , 118, 802-812	8.7	9
42	Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer. <i>European Urology</i> , <b>2018</b> , 73, 949-960	10.2	9
41	The influence of mesenchyme of neonatal seminal vesicle and embryonic urogenital sinus on the morphologic and functional cytodifferentiation of dunning prostatic adenocarcinoma: Roles of growth factors and proto-oncogenes. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>1997</b> , 3, 85-93	2.8	9

40	The evolutionarily conserved long non-coding RNA LINC00261 drives neuroendocrine prostate cancer proliferation and metastasis via distinct nuclear and cytoplasmic mechanisms. <i>Molecular Oncology</i> , <b>2021</b> , 15, 1921-1941	7.9	9
39	Elevated XPO6 expression as a potential prognostic biomarker for prostate cancer recurrence. <i>Frontiers in Bioscience - Scholar</i> , <b>2016</b> , 8, 44-55	2.4	9
38	Well-Differentiated Papillary Mesothelioma of the Peritoneum Is Genetically Distinct from Malignant Mesothelioma. <i>Cancers</i> , <b>2020</b> , 12,	6.6	8
37	Conditionally Reprogrammed Cells from Patient-Derived Xenograft to Model Neuroendocrine Prostate Cancer Development. <i>Cells</i> , <b>2020</b> , 9,	7.9	8
36	Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer. <i>BMC Cancer</i> , <b>2015</b> , 15, 874	4.8	8
35	Lessons from in-vivo models of castration-resistant prostate cancer. <i>Current Opinion in Urology</i> , <b>2013</b> , 23, 214-9	2.8	8
34	Changes in serum and tissue zinc levels in sex hormone-induced prostatic carcinogenesis in the noble rat. <i>Tumor Biology</i> , <b>2000</b> , 21, 328-36	2.9	8
33	LncRNA promotes taxane resistance in castration-resistant prostate cancer via a BCL2A1-dependent mechanism. <i>Epigenomics</i> , <b>2020</b> , 12, 1123-1138	4.4	7
32	Pre-clinical Models for Malignant Mesothelioma Research: From Chemical-Induced to Patient-Derived Cancer Xenografts. <i>Frontiers in Genetics</i> , <b>2018</b> , 9, 232	4.5	7
31	Potential Therapies for Infectious Diseases Based on Targeting Immune Evasion Mechanisms That Pathogens Have in Common With Cancer Cells. <i>Frontiers in Cellular and Infection Microbiology</i> , <b>2019</b> , 9, 25	5.9	6
30	A meta-analysis approach for characterizing pan-cancer mechanisms of drug sensitivity in cell lines. <i>PLoS ONE</i> , <b>2014</b> , 9, e103050	3.7	6
29	Prostate cancer metastasis-driving genes: hurdles and potential approaches in their identification. <i>Asian Journal of Andrology</i> , <b>2014</b> , 16, 545-8	2.8	6
28	Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response.. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2022</b> , 41, 105	12.8	6
27	Aneustat (OMN54) has aerobic glycolysis-inhibitory activity and also immunomodulatory activity as indicated by a first-generation PDX prostate cancer model. <i>International Journal of Cancer</i> , <b>2018</b> , 143, 419-429	7.5	5
26	T-type calcium channels drive the proliferation of androgen-receptor negative prostate cancer cells. <i>Prostate</i> , <b>2019</b> , 79, 1580-1586	4.2	5
25	Chromoplexy: a new paradigm in genome remodeling and evolution. <i>Asian Journal of Andrology</i> , <b>2013</b> , 15, 711-2	2.8	5
24	Doxorubicin-loaded graphene oxide nanocomposites in cancer medicine: Stimuli-responsive carriers, co-delivery and suppressing resistance.. <i>Expert Opinion on Drug Delivery</i> , <b>2022</b> ,	8	5
23	Is HOTAIR really involved in neuroendocrine prostate cancer differentiation?. <i>Epigenomics</i> , <b>2018</b> , 10, 1259-1261	4.4	4

22	Rescue and isolation of Rb-deficient prostate epithelium by tissue recombination. <i>Methods in Molecular Biology</i> , <b>2003</b> , 218, 17-33	1.4	3
21	Activity of NEO2734, a novel dual inhibitor of both BET and CBP-P300, in SPOP-mutated prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 62-62	2.2	3
20	TMEM45B is a novel predictive biomarker for prostate cancer progression and metastasis. <i>Neoplasia</i> , <b>2018</b> , 65, 815-821	3.3	3
19	: an insight into lncRNA genetic evolution. <i>Epigenomics</i> , <b>2021</b> , 13, 1831-1843	4.4	3
18	Treatment-emergent neuroendocrine prostate cancer: molecularly driven clinical guidelines. <i>International Journal of Endocrine Oncology</i> , <b>2019</b> , 6, IJE20	0.3	3
17	Prevention of Prostate Tumor Development by Stimulation of Antitumor Immunity Using a Standardized Herbal Extract (Deep Immune ) in TRAMP Mice. <i>Evidence-based Complementary and Alternative Medicine</i> , <b>2018</b> , 2018, 9707543	2.3	3
16	Response to Savaskan NE et al. The x cystine/glutamate antiporterA potential target for therapy of cancer and other diseases: Yet another cytotoxic anticancer approach? <i>Journal of Cellular Physiology</i> , <b>2009</b> , 220, 533-534	7	2
15	Establishment and characterization of a novel treatment-related neuroendocrine prostate cancer cell line KUCaP13. <i>Cancer Science</i> , <b>2021</b> , 112, 2781-2791	6.9	2
14	SPOP mutation induces DNA methylation via stabilizing GLP/G9a. <i>Nature Communications</i> , <b>2021</b> , 12, 57167.4	6.4	2
13	SPOP mutation induces replication over-firing by impairing Geminin ubiquitination and triggers replication catastrophe upon ATR inhibition. <i>Nature Communications</i> , <b>2021</b> , 12, 5779	17.4	2
12	MOLECULAR ANALYSIS AND CHARACTERIZATION OF PrEC, COMMERCIALY AVAILABLE PROSTATE EPITHELIAL CELLS. <i>In Vitro Cellular and Developmental Biology - Animal</i> , <b>2006</b> , 42, 33	2.6	1
11	Patient-derived xenograft models of neuroendocrine prostate cancer. <i>Cancer Letters</i> , <b>2022</b> , 525, 160-169.9	9.9	1
10	Long Non-coding RNAs and Cancer CellsDrug Resistance: An Unexpected Connection. <i>RNA Technologies</i> , <b>2020</b> , 167-198	0.2	1
9	Biological and Clinical Evidence for Metabolic Dormancy in Solid Tumors Post Therapy. <i>Cancer Drug Discovery and Development</i> , <b>2017</b> , 17-29	0.3	1
8	Immuno-oncology of Dormant Tumours. <i>Cancer Drug Discovery and Development</i> , <b>2017</b> , 51-60	0.3	1
7	Androgen receptor (AR) antagonism triggers acute succinate-mediated adaptive responses to reactivate AR signaling. <i>EMBO Molecular Medicine</i> , <b>2021</b> , 13, e13427	12	1
6	GRB10 sustains AR activity by interacting with PP2A in prostate cancer cells. <i>International Journal of Cancer</i> , <b>2021</b> , 148, 469-480	7.5	1
5	Prospectives. <i>Molecular and Translational Medicine</i> , <b>2017</b> , 193-200	0.4	

4	Patient-Derived Tumor Xenografts: Historical Background. <i>Molecular and Translational Medicine</i> , <b>2017</b> , 1-9	0.4
3	Hormonal Carcinogenesis: The Role of Estrogens <b>2017</b> , 307-322	
2	The Non-Coding Transcriptome as a Dynamic Regulator of Prostate Cancer Metastasis. <i>FASEB Journal</i> , <b>2015</b> , 29, 221.3	0.9
1	ZRSR2 overexpression is a frequent and early event in castration-resistant prostate cancer development. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2021</b> , 24, 775-785	6.2